Literature DB >> 2939092

Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.

H Osswald, M Youssef.   

Abstract

The combination of mitoxantrone with lucanthone, a schistosomicidal and nonmyelotoxic agent, yielded a therapeutic synergism in L 1210 and P 388 leukemia with no increase in toxicity. In that combination the nonmyelotoxic lucanthone enabled the use of the optimal dose of mitoxantrone. The recent hypothesis that planar polycyclic aromatic compounds, mostly comprised by the term intercalators, intercalate with DNA or bind to DNA may need receiving with respect to membrane target sites.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2939092     DOI： 10.1007/bf00400752

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  14 in total

1.  A SYSTEMATIC INVESTIGATION OF THIOXANTHEN-9-ONES AND ANALOGS AS POTENTIAL ANTITUMOR AGENTS.

Authors:  E J BLANZ; F A FRENCH
Journal:  J Med Chem       Date:  1963-03       Impact factor: 7.446

2.  Effects of miracil D, amodiaquin, and a series of other 10thiaxanthenones and 4-aminoquinolines against a variety of experimental tumors in vitro and in vivo.

Authors:  E HIRSCHBERG; A GELLHORN; M R MURRAY; E F ELSLAGER
Journal:  J Natl Cancer Inst       Date:  1959-03       Impact factor: 13.506

Review 3.  Molecular and biochemical pharmacology of mitoxantrone.

Authors:  F E Durr; R E Wallace; R V Citarella
Journal:  Cancer Treat Rev       Date:  1983-12       Impact factor: 12.111

4.  Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new anthracenedione antineoplastic agents.

Authors:  E D Kharasch; R F Novak
Journal:  Biochem Biophys Res Commun       Date:  1982-10-15       Impact factor: 3.575

5.  Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz; F Traganos; M R Melamed
Journal:  Biochem Pharmacol       Date:  1981-02-01       Impact factor: 5.858

6.  Interaction of antitumor agents including doxorubicin or daunorubicin in sarcoma-180 system.

Authors:  M Iigo; F Kanzawa; A Nakamura; A Hoshi; K Kuretani
Journal:  Gan       Date:  1977-08

7.  Biologic and biochemical effects of mitoxantrone.

Authors:  F E Durr
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

8.  Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.

Authors:  R E Wallace; K C Murdock; R B Angier; F E Durr
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

9.  Experimental antitumor activity of aminoanthraquinones.

Authors:  R K Johnson; R K Zee-Cheng; W W Lee; E M Acton; D W Henry; C C Cheng
Journal:  Cancer Treat Rep       Date:  1979-03

10.  Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.

Authors:  S Fujimoto; M Ogawa
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more
  1 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.